Abstracts Archive - Page 160 of 2425 - ACR Meeting Abstracts

Abstract Number: 0712 • ACR Convergence 2024
Efficacy of Sacubitril/Valsartan in Patients with Systemic Sclerosis and Heart Failure: A Retrospective Analysis
Nouran Eshak¹, Mahmoud Abdelnabi², Jaxon Quillen¹, Michael Pham¹, Joseph Hentz¹ and Vivek Nagaraja¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Phoenix, AZ
Background/Purpose: Cardiac involvement in systemic sclerosis (SSc) is common, underdiagnosed, and manifests variably. Myocardial involvement can manifest as left heart failure with preserved or reduced…
Abstract Number: 0760 • ACR Convergence 2024
A Macrophage-smooth Muscle Cell Axis Influences Vascular Remodeling Through Activation of the EGFR Pathway in Giant Cell Arteritis
Kevin Chevalier¹, Léa Dionet¹, Paul Breillat¹, Margot Poux¹, Julien Dang¹, Benoit Terris², Patrick Bruneval³, Luc Mouthon⁴, Olivia Lenoir¹, Tharaux Pierre-Louis¹ and Benjamin Terrier⁵, ¹Paris Cardiovascular Research Center, INSERM U970, Paris, France, ²Department of pathology, Hôpital Cochin, GHU Paris Centre, AP-HP, Université Paris Cité,, Paris, France, ³Department of Pathology, Hôpital Européen Georges Pompidou, GHU Paris Centre, AP-HP, Université Paris Cité, Paris, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁵Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) is a granulomatous vasculitis affecting large vessels. The role of macrophages and vascular smooth muscle cells (VSMC) appears to be…
Abstract Number: 0696 • ACR Convergence 2024
MRI DAVIX Index Is an Imaging Biomarker for Endothelial Damage of Systemic Sclerosis Digital Ulcers
Stefano Di Donato¹, Rebecca Ross², Yassir El-Sherbiny³, Riccardo Bixio⁴, Marco Minerba⁵, Christopher Wasson⁶, Jun Li⁷, Jochen SCHMITZ⁸, Sudha Visvanathan⁹ and Francesco Del Galdo⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³Nottingham Trent University, Nottingham, United Kingdom, ⁴University of Verona, Verona, Verona, Italy, ⁵1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom, ⁷Boehringer Ingelheim, Danbury, CT, ⁸Boehringer-Ingelheim, Ridgefield, CT, ⁹Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT
Background/Purpose: Circulating endothelial cells (CEC) and their precursors have been shown to correlate to the severity of vascular manifestations in Systemic sclerosis1, such as Digital…
Abstract Number: 0688 • ACR Convergence 2024
Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces the Risk of Vascular Complication Leading to Treatment Escalation: Emulation of a Target Trial Using Time-dependent Propensity Score-matching
Enrico De Lorenzis¹, Gerlando Natalello², Fabio Cacciapaglia³, Rossella De Angelis⁴, Edoardo Cipolletta⁵, Veronica Codullo⁶, Giacomo De Luca⁷, Dilia Giuggioli⁸, Francesca Ingegnoli⁹, Valeria Riccieri¹⁰, Maria Antonietta D'Agostino¹¹, Clodoveo Ferri¹², Marco Matucci Cerinic¹³ and Silvia Laura Bosello¹⁴, ¹Catholic University of the Sacred Heart, Roma, Rome, Italy, ²Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ³Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁴Polytechnic University of Marche, Ancona, Italy, Ancona, Italy, ⁵Polytechnic University of Marche, Ancona, Italy, ⁶Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ⁷Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁸Scleroderma Unit, University of Modena and Reggio Emilia, Modena, Italy, ⁹Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Research Center for Environmental Health, Università degli Studi di Milano, Milan, Italy, ¹⁰Department of Rheumatology, La Sapienza University of Rome, Rome, Italy, ¹¹Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ¹²Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy, ¹³Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ¹⁴Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: The prescription of Mycophenolate Mofetil (MMF) represents the primary treatment for interstitial lung disease (ILD) associated with systemic sclerosis (SSc) and is an option…
Abstract Number: 0762 • ACR Convergence 2024
Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications
Helena M Amar Muñoz¹, Juan Molina-Collada¹, Isabel Castrejon², irene monjo³, Elisa Fernández-Fernández:⁴, José María Álvaro-Gracia⁵ and Eugenio De Miguel⁶, ¹Hospital General Universitario Gregorio Marañón, MADRID, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁵Hospital Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischemic complications (IC) in giant cell arteritis (GCA).Methods: Retrospective…
Abstract Number: 0764 • ACR Convergence 2024
Primary Treatment Failure to Tocilizumab in Giant Cell Arteritis
Paul Cioni¹, Hubert de Boysson², Simon Parreau³, Perrine SMETS⁴, Maxime SAMSON⁵, Sara Melboucy⁶, Herve Lobbes⁷, Nabil Belfeki⁸, François Perrin⁹, Pascal Maurice Rossi¹⁰, Eric Liozon¹¹, Guillaume Le Guenno¹², Claire Le Jeunne¹, OLIVIER FOGEL¹³, Lola Prat¹⁴, Florent Ladouce¹⁵, Sylvie Grosleron¹⁶, Halil Yildiz¹⁷, Vincent Grosbost¹⁵, Xavier Puéchal¹⁸, Chloe Comarmond¹⁹ and Benjamin Terrier²⁰, ¹Cochin University Hospital, Paris, France, ²Caen university Hospital, Caen, France, ³Dupuytren hospital, Limoges, France, ⁴Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁵Dijon University Hospital, Dijon, France, ⁶CH Saint Quentin, Saint Quentin, France, ⁷CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸GHSIF - Melun, Melun, France, ⁹CH Saint Nazaire, Saint Nazaire, France, ¹⁰CHU Hopital Nord Marseille, Marseille, France, ¹¹CHU Limoges, Limoges, France, ¹²CHU, Clermont-Ferrand, France,, Clermont-Ferrand, France, ¹³AP-HP, Paris, France, ¹⁴Jacques Cartier Hospital, Massy, France, ¹⁵Clermont Ferrand University Hospital, Clermont Ferrand, France, ¹⁶CH Agen-Nerac, Agen, France, ¹⁷Saint-Luc University Clinic, Bruxells, Belgium, ¹⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁹Lariboisière University Hospital, Paris, France, ²⁰Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over the age of 50. Glucocorticoids are the cornerstone of treatment for GCA,…
Abstract Number: 0767 • ACR Convergence 2024
Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis
Alison Clifford¹, Jonathan Abele¹, Ryan Hung¹, Paolo Raggi¹, Frank Wuest¹, Jan Andersson¹, Elaine Yacyshyn², Eric Lenza¹, Glen Jickling¹ and Jan Willem Cohen Tervaert¹, ¹University of Alberta, Edmonton, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: 18F-fluoro-deoxyglucose (FDG) is the current standard among radiotracers for PET/CT imaging of large vessel vasculitis (LVV) in giant cell arteritis (GCA), but its performance…
Abstract Number: 0763 • ACR Convergence 2024
Transcriptional Analysis of Both Normal and Abnormal TABs in Biopsy-proven GCA Reveals a Shared Gene Expression Profile Compared to Clinically Diverse Controls
Ingrid Lindquist¹, Dongseok Choi², Suzanne Fei³, Kiana Vakil-Gilani⁴, Daniela Ghetie¹, David Wilson⁵, Diva Salomao⁶, Hillary Stiefel⁷, Daniel Albert⁷, James Rosenbaum⁸ and Marcia Friedman¹, ¹OHSU, Division of Arthritis and Rheumatic Diseases, Portland, OR, ²OHSU, School of Public Halth, Portland, OR, ³OHSU, Oregon National Primate Research Center, Portland, OR, ⁴OHSU, Division of Arthritis and Rheumatic Diseases, Porltand, OR, ⁵OHSU, Casey Eye Institute, Porrtland, OR, ⁶Mayo Clinic, Division of Anatomic Pathology, Rochester, MN, ⁷OHSU, Casey Eye Institute, Portland, OR, ⁸Corvus Pharmaceuticals and Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over 50 years old and is a clinical diagnosis bolstered by pathologic findings on temporal…
Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Andrew Sternlicht¹, Michael Shanahan², Erin Morton², Meredith Todd³, Ivana Hunt², Zoey Reed², amanda weragoda⁴, Lashika Weerakoon² and Elizabeth Briggs², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Flinders Medical Centre, Adelaide, Australia, ³Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia, ⁴F, Adelaide, Australia
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…
Abstract Number: 0698 • ACR Convergence 2024
Association of Systemic Sclerosis with ANCA-Associated Vasculitis and Large Vessel Vasculitis: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder with excessive fibrosis and vasculopathy. While typically non-inflammatory, frank vasculitis can complicate SSc. Concomitant SSc with ANCA-associated…
Abstract Number: 0774 • ACR Convergence 2024
A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose Glucocorticoids Compared to Stopping Glucocorticoids to Maintain Remission of Granulomatosis with Polyangiitis: The TAPIR Trial
Peter Merkel¹, Christian Pagnoux², Nader Khalidi³, Ulrich Specks⁴, Curry Koening⁵, Carol Langford⁶, Larry Moreland⁷, Paul Monach⁸, Jason Springer⁹, Shubhasree Banerjee¹, Simon Carette¹⁰, Rennie Rhee¹, Medha Soowamber¹¹, Kenneth Warrington⁴, Renee Borchin¹², Cristina Burroughs¹³, Carol McAlear¹, David Cuthbertson¹³ and Jeffrey Krischer¹³, ¹University of Pennsylvania, Philadelphia, PA, ²Mount Sinai Hospital, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Mayo Clinic, Rochester, MN, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Colorado, Denver, CO, ⁸VA Boston Healthcare System, Boston, MA, ⁹Vanderbilt University Medical Center, Franklin, TN, ¹⁰Mount Sinai Hosptial, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²University of South Florida, Tampa, ¹³University of South Florida, Tampa, FL
Background/Purpose: Use of low-dose glucocorticoids to maintain remission in patients with granulomatosis with polyangiitis (GPA) remains controversial. Additionally, there is no consensus on how to…
Abstract Number: 0706 • ACR Convergence 2024
Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Carleigh Zahn¹, Scott Visovatti², Rosemary Gedert¹, Suiyuan Huang¹, Victor Moles¹, Amber Young¹, Vallerie McLaughlin¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²The Ohio State University, Columbus
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of mortality in systemic sclerosis (SSc). We launched an IRB approved prospective study (NOVEL) in 2013 at…
Abstract Number: 0676 • ACR Convergence 2024
Understanding the Patient Burden of Lupus: Insights from Multi-Faceted Ethnography Research
Jeanette Andersen¹, Ina Meyer², Neeta Camadoo³, Tracy Machado⁴, Shreya Saraf⁴ and Mohamed Akrout², ¹Lupus Europe, Brussels, Belgium, ²F. Hoffmann-La Roche Ltd, Basel, ³Roche Products Ltd, Welwyn Garden City, ⁴Elma Research International, London
Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease that affects multiple organs, including the skin, joints, lungs, heart, kidneys and brain.…
Abstract Number: 0777 • ACR Convergence 2024
Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients
Theodoros Ioannis Papadimitriou¹, Jing Jing Wang², Xuehui He³, Sidney van der Zade⁴, Massis Krekorian⁵, Prashant Singh⁶, Erik Dik⁵, Ger Pruijn⁵, Tom Gordon², Hans Koenen⁷, Martijn Huijnen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Flinders University, Adeleide, Australia, ³Radboudumc, Nijmegen, Netherlands, ⁴Radboudumc, Amsterdam, Netherlands, ⁵Radboudumc, Nijmegen, Gelderland, Netherlands, ⁶Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands
Background/Purpose: Sjögren’s syndrome (SjS) is a chronic inflammatory disorder, characterized by formation of autoantibodies. Over time rheumatoid factor (RF) clones can give rise to cryoglobulinemic…
Abstract Number: 0772 • ACR Convergence 2024
Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis
Andreas Kerschbaumer¹, Marlene Steiner², Suzanne D. Khalili¹, Daniel Aletaha³ and Josef Smolen⁴, ¹Medical University of Vienna, Vienna, Wien, Austria, ²Medical University Vienna, Vienna, Wien, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with psoriatic arthritis (PsA). Since the advent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].